Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Phosphoric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | SLC34A1 | Q06495 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 4/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.36 |
| ▸ | PEPD | P12955 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL29145675 | 1.00 | LMNA (0.47) | LMNASLC34A1CA4CA1CA2 | |
| Phosphoric Acid SCHEMBL1401797 | 0.96 | LMNA (0.44) | LMNASLC34A1CA4CA1CA2 | |
| Phosphoric Acid SCHEMBL28272622 | 0.91 | LMNA (0.47) | LMNASLC34A1CA4CA1CA2 | |
| Phosphoric Acid SCHEMBL28145512 | 0.91 | LMNA (0.47) | LMNASLC34A1CA4CA1CA2 | |
| Phosphoric Acid SCHEMBL28133941 | 0.91 | LMNA (0.47) | LMNASLC34A1CA4CA1CA2 | |
| Phosphoric Acid SCHEMBL6321642 | 0.91 | — | — | |
| Phosphoric Acid SCHEMBL7083907 | 0.91 | LMNA (0.47) | LMNASLC34A1CA4CA1CA2 | |
| Phosphoric Acid SCHEMBL5610258 | 0.91 | SLC34A1 (0.54) | LMNASLC34A1CA4CA1CA2 | |
| Phosphoric Acid SCHEMBL15270770 | 0.91 | LMNA (0.47) | LMNASLC34A1CA4CA1CA2 | |
| Phosphoric Acid SCHEMBL28108693 | 0.91 | LMNA (0.47) | LMNASLC34A1CA4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1389102-B1 | USE OF LANTHANUM CARBONATE FOR THE PREVENTION OF KIDNEY STONE DISEASE | SHIRE INT LICENSING BV (NL) | 2011-03-02 | — | — | EP | disclosed |
| US-20070116782-A1 | USE OF RARE EARTH COMPOUNDS FOR THE PREVENTION OF KIDNEY STONE DISEASE | SHIRE INTERNATIONAL LICENSING B.V. (NL) | 2007-05-24 | — | — | US | disclosed |
| US-7192609-B2 | Use of rare earth compounds for the prevention of kidney stone disease | SHIRE INTERNATIONAL LICENSING B.V. (NL) | 2007-03-20 | — | — | US | disclosed |
| EP-1389102-A4 | USE OF RARE EARTH COMPOUNDS FOR THE PREVENTION OF KIDNEY STONE DISEASE | ANORMED INC (CA) | 2004-07-14 | — | — | EP | disclosed |
| EP-1389102-A1 | USE OF RARE EARTH COMPOUNDS FOR THE PREVENTION OF KIDNEY STONE DISEASE | ANORMED INC. (CA) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002085348-A1 | USE OF RARE EARTH COMPOUNDS FOR THE PREVENTION OF KIDNEY STONE DISEASE | ANORMED INC. (CA) | 2002-10-31 | — | — | WO | disclosed |
| US-20020155168-A1 | Use of rare earth compounds for the prevention of kidney stone disease | SHIRE INTERNATIONAL LICENSING B.V. (NL) | 2002-10-24 | — | — | US | disclosed |